Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Conditions
- Stage IV Non-small Cell Lung Cancer
- Stage IV Melanoma
- Triple Negative Breast Cancer
- Renal Cell Carcinoma Stage IV
Interventions
- COMBINATION_PRODUCT: ImmunicomAIAC
Sponsor
Dr. Ronnie Shapira
Collaborators